JOSH BILENKER

Josh Bilenker, MD, is a proven biopharmaceutical executive who is best known for founding Loxo Oncology and serving as its CEO. Since the acquisition of Loxo Oncology by Eli Lilly and Co. in 2019, Dr. Bilenker.has been working to reorganize the oncology R&D efforts of this multinational pharmaceutical company. Josh Bilenker, MD, entered the pharmaceutical industry following a career as a healthcare venture capital investor at Aisling Capital, from 2006 to 2019.